Transgene enters new phase in its strategic development
- New funding of up to ?30 million secured
- Restructuring finalised, giving way to ambitious clinical development plan
Strasbourg, France, January 7, 2016 – Transgene SA (Euronext Paris: TNG) today announced its new strategic development plan, as well as the securing of new financing and the completion of its restructuring program.
Following the completion of its restructuring plan, launched at the end of June 2015, Transgene announced its strategy based on its unique and well-known strengths in the immune-engineering of viral vectors and on its expertise in pre-clinical and clinical development. Transgene will, as a priority, combine its products with other immunotherapy products, including immune checkpoint inhibitors (ICI), a new class of promising therapeutics for the treatment of cancers and infectious diseases.
In pre-clinical studies, the results obtained by Transgene, as well as those reported in recent scientific journals using comparable approaches, demonstrate the potential and the rationale of combining immunotherapeutics. The principle of a strong interaction between viral vector-based immunotherapies and ICI’s is validated by a number of current clinical programs. In strengthening the immune response through two complementary mechanisms of action, these combinations should increase treatment efficacy.